Lifeboat Foundation

The solution was to split the protein into two harmless halves. Liu’s team, led by graduate student Beverly Mok, used 3D imaging data from the Mougous lab to work out how to divide the protein into two pieces. Each piece did nothing on its own, but when reunited, they reconstituted the protein’s full activity. The team fused each deaminase half to customizable DNA-targeting proteins that did not require guide RNAs. Those proteins bound to specific stretches of DNA, bringing the two halves of the deaminase together. That let the molecule regain its function and work as a precision gene editor—but only once it was correctly positioned.

Liu’s team used the technology to make precise changes to specific mitochondrial genes. Then, Mootha’s lab, which focuses on mitochondrial biology, ran tests to see whether the edits had the intended effect. “You could imagine that if you’re introducing editing machinery into the mitochondria, you might accidentally cause some sort of a catastrophe,” Mootha said. “But it was very clean.” The entire mitochondrion functioned well, except for the one part the scientists intentionally edited, he explained.

This mitochondrial base editor is just the beginning, Mougous suggested. It can change one of the four DNA letters into another. He hopes to find additional deaminases that he and Liu can develop into editors able to make other mitochondrial DNA alterations. Such tools could enable new strategies for treating mitochondrial diseases, as well as help scientists to model diseases and aid in drug testing. “The ability to precisely install or correct pathogenic mutations could accelerate the modeling of diseases caused by mtDNA mutations, facilitate preclinical drug candidate testing, and potentially enable therapeutic approaches that directly correct pathogenic mtDNA mutations,” the authors noted. “Bacterial genomes contain various uncharacterized deaminases, raising the possibility that some may possess unique activities that enable new genome-editing capabilities.”

Spiders produce amazingly strong and lightweight threads called draglines that are made from silk proteins. Although they can be used to manufacture a number of useful materials, getting enough of the protein is difficult because only a small amount can be produced by each tiny spider. In a new study published in Communications Biology, a research team led by Keiji Numata at the RIKEN Center for Sustainable Resource Science (CSRS) reported that they succeeded in producing the spider silk using photosynthetic bacteria. This study could open a new era in which photosynthetic bio-factories stably output the bulk of spider silk.

In addition to being tough and lightweight, silks derived from arthropod species are biodegradable and biocompatible. In particular, spider silk is ultra-lightweight and is as tough as steel. “Spider silk has the potential to be used in the manufacture of high-performance and durable materials such as tear-resistant clothing, automobile parts, and aerospace components,” explains Choon Pin Foong, who conducted this study. “Its biocompatibility makes it safe for use in biomedical applications such as drug delivery systems, implant devices, and scaffolds for tissue engineering.” Because only a trace amount can be obtained from one spider, and because breeding large numbers of spiders is difficult, attempts have been made to produce artificial spider silk in a variety of species.

The CSRS team focused on the marine photosynthetic bacterium Rhodovulum sulfidophilum. This bacterium is ideal for establishing a sustainable bio-factory because it grows in seawater, requires carbon dioxide and nitrogen in the atmosphere, and uses solar energy, all of which are abundant and inexhaustible.

Rigid electromagnetic actuators have a variety of applications, but their bulky nature limits human-actuator integration or machine-human collaborations. In a new report on Science Advances, Guoyong Mao and a team of scientists in soft matter physics and soft materials at the Johannes Kepler University Linz, Austria, introduced soft electromagnetic actuators (SEMAs) to replace solid metal coils with liquid-metal channels embedded in elastomeric shells. The scientists demonstrated the user-friendly, simple and stretchable construct with fast and durable programmability.

They engineered a SEMA based soft miniature shark and a multi-coil flower with individually controlled petals, as well as a cubic SEMA to perform arbitrary motion sequences. The team adapted a numerical model to support device miniaturization and reduce power consumption with increased mechanical efficiency. The SEMAs are electrically controlled shape-memory systems with applications to empower soft grippers for minimally invasive medical applications. The scientists highlighted the practicality of small size and multi-coil SEMAs for promising applications in medicine, much like in the classic sci-fi movie “Fantastic Voyage,” in which a miniature submarine destroyed a blood clot to save a patient’s life. In reality, Mao et al. aim to develop and deploy SEMA-based advanced microrobots for such futuristic medical applications, including drug delivery and tissue diagnostics with nano-precision.

By genetically engineering thale cress, scientists have made it grow like a succulent, more than doubling the plant’s water-use efficiency.

Sable co-created the story with artist Kristian Donaldson (Unthinkable, The Guild) and Mey Rude, a transgender woman who served as a consulting editor on the project. Sable took some time to talk to SYFY WIRE about biohacking, transhumanism, and how science fiction often predicts the future.

The Dark, by screenwriter and playwright Mark Sable (Unthinkable, Godkillers), is a graphic novel about a world plunged into chaos when a biotech virus pulls everything offline. The plot twists around government conspiracies, techno warfare, biohacking, and the unlikely pair out to stop it before another world war breaks loose. To make it all the scarier, Sable bases his fiction on fact. As a futurist who has consulted with think tanks and The Art of Future Warfare Project, he is well versed in techno warfare scenarios.

The Dark begins in 2035 and follows Master Sergeant Robert Carter, a N.E.O. (Networked Exoskeleton Operator) Marine whose power armor links him to the world’s technology, and whose implants mentally connect him to his unit. He feels what they feel, which proves torturous when his unit is attacked. The Dark takes on a double meaning as the experience leaves him both physically and technologically blind as the world’s tech crashes.

Continue reading “Indie Comics Spotlight: Biohacking, transhumanism, and gender identity in ‘The Dark’” »

Dean Kamen, the inventor of the Segway, is currently spearheading a project to convert part of the old New Hampshire textile plant into a factory for lab-grown lungs, livers, and other organs for transplantation — and he doesn’t think it’ll take long to do it.

The nonprofit is like a club for tissue engineering and regenerative medicine researchers. Groups must have something to offer in order to join (money, equipment, experience), but once a part of ARMI, they gain access to the other members’ research and resources.

Three studies showing large DNA deletions and reshuffling heighten safety concerns about heritable genome editing.

To create artificial general intelligence, we need to study the brain.

:oooooo.

CRISPR-Cas9 is a revolutionary gene-editing technology that offers the potential to treat diseases such as cancer, but the effects of CRISPR in patients are currently unknown. Stadtmauer et al. report a phase 1 clinical trial to assess the safety and feasibility of CRISPR-Cas9 gene editing in three patients with advanced cancer (see the Perspective by Hamilton and Doudna). They removed immune cells called T lymphocytes from patients and used CRISPR-Cas9 to disrupt three genes (TRAC, TRBC, and PDCD1) with the goal of improving antitumor immunity. A cancer-targeting transgene, NY-ESO-1, was also introduced to recognize tumors. The engineered cells were administered to patients and were well tolerated, with durable engraftment observed for the study duration. These encouraging observations pave the way for future trials to study CRISPR-engineered cancer immunotherapies.

Science, this issue p. eaba7365; see also p. 976.